Stereotaxis said GenesisX is its most accessible robotic system to date. | Source: Stereotaxis
Stereotaxis Inc. today announced that it has secured the first order for its latest-generation robotic system, GenesisX. The surgical robot developer said the system is geared towards minimally invasive endovascular intervention.
“We are thrilled to announce the first firm order for GenesisX from a pioneering European hospital,” said David Fischel, chairman and CEO of Stereotaxis. “Establishing the first GenesisX robotic lab is a critical milestone for us as we advance towards full commercial launch.”
“We look forward to demonstrating the performance and reliability of GenesisX in the demanding clinical environment,” he added. “GenesisX promises to transform the accessibility of robotic magnetic navigation and is central to our mission of driving broad robotic adoption throughout endovascular surgery.”
GenesisX advances magnetic navigation
GenesisX builds on the benefits of robotic magnetic navigation (RMN) while making the technology more accessible for healthcare providers, according to Stereotaxis. The system does this with two improvements. First, it uses smaller magnets, said the St. Louis, Mo.-based company.
Second, it incorporates magnetic shielding into its structure in place of the shielding otherwise installed in the walls of the operating room.
These features mean the system requires no structural anchoring through the floor and operates using standard 120/230V power outlets, Stereotaxis said. Instead, a single fiber is routed from each robot to the system cabinet. This cabinet is 80% smaller than previous cabinets and can fit under a table in the operating room.
Stereotaxis noted that GenesisX is smaller and lighter than its previous-generation system. In addition, the company claimed that the system maintains its standards in speed, responsiveness, and efficient workflow.
Save now with early bird discount
Stereotaxis marks 2024 progress and 2025 plans
Stereotaxis hit a number of milestones in 2024, which included:
- In May, the company established the first robotic heart procedure program in Italy at Hospital Santa Maria della Pietà in Naples. With the program, doctors can treat patients with heart rhythm disorders using robotic ablation procedures. The hospital became the first in Italy to adopt the Stereotaxis Genesis RMN system.
- Later that month, Stereotaxis received CE Mark for its devices in Europe under the new European Medical Device Regulation, or EU MDR, framework. The recertification under MDR covers all Stereotaxis devices available in Europe.
- In November, it announced that physicians at the University of Kansas Health System successfully treated the first patients with its Genesis system. The use of the Genesis system came as part of a robotic heart program at the health system.
- The company’s Genesis surgical robot received regulatory approval in China. Stereotaxis said it marks a “significant milestone” as it expands access to minimally invasive robotic technology in China.
During 2025, Stereotaxis said it plans to gain regulatory approvals in Europe and the U.S. for a portfolio of compatible electrophysiology (EP) and vascular catheters, demonstrate real-world use of GenesisX, and enhance the compatibility of GenesisX with various X-rays. The company will also prepare supply chain, manufacturing, installation, and commercial processes for a full launch.
Tell Us What You Think!